Genomtec S.A. (FRA:4VI)

Market Cap	16.52M -32.3%
Revenue (ttm)	6.98K +400.0%
Net Income	-2.14M
EPS	-0.14
Shares Out	n/a
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	n/a
Open	0.9850
Previous Close	0.9700
Day's Range	0.9810 - 0.9850
52-Week Range	0.7120 - 1.6760
Beta	n/a
Analysts	n/a
Price Target	n/a
Earnings Date	Jun 1, 2026

About Genomtec

Genomtec S.A. researches and develops a mobile point of care genetic testing platform for the clinical diagnostics market in Poland. The company’s flagship project is the Genomtec ID, a diagnostic platform that offer mobile genetic diagnosis to patients through streamlined nucleic acid amplification technology (SNAAT) to detect viruses, bacteria, and fungi, as well as genetic mutations by analysis of biological material of patients using swabs, urine, and saliva. It also develops SNAAT chemistry for mutation detection in oncology. In addition, ...

• Industry: Biological Products, Except Diagnostic Substances
• Founded: 2008
• Employees: 32
• Stock Exchange: Frankfurt Stock Exchange
• Ticker Symbol: 4VI

Financial Performance

In 2025, Genomtec's revenue was 19,000, an increase of 1800.00% compared to the previous year's 1,000. Losses were -10.22 million, -8.80% less than in 2024.

Financial numbers in PLN

Data Source: S&P Global Market Intelligence

Fundamental and historical data is provided by S&P Global Market Intelligence.

Last checked:

Jun 27, 2026

Data Sources Report a data error